- |||||||||| hydrochlorothiazide / Generic mfg.
Journal: A Rare Case of Pulmonary Edema Secondary to Hydrochlorothiazide Use. (Pubmed Central) - Nov 17, 2024 Prompt supportive care and discontinuation of the medication is necessary to prevent and manage such a complication. This case report describes a patient who developed noncardiogenic pulmonary edema after taking a combination pill of hydrochlorothiazide-losartan.
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Journal: Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021. (Pubmed Central) - Oct 16, 2024 We explored the associations between patent exclusivity loss, per-pill costs, and Medicare Part D enactment on medication use over time, focusing on the most commonly used medications (lisinopril, amlodipine, losartan, hydrochlorothiazide, and metoprolol)...The increase in antihypertensive medication use over the past decades highlights the significant impact of loss of patent exclusivity on the uptake in the use of specific medications. These findings underscore the complexity of factors influencing medication use, beyond cost reductions alone, and suggest that policies need to consider multiple facets to effectively improve antihypertensive medication accessibility and utilization.
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Vaping-Induced Acute Tubular Necrosis () - Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4936; His BP medications included amlodipine, Hydrochlorothiazide, and losartan.On exam, he was hypertensive with a BP of 240/130, appeared volume overloaded, and was progressively hypoxic...Healthcare providers should be aware of the risks associated with e-cigarettes, including potential kidney injury.. . .
- |||||||||| CODE STEMI Due to Excessive Ingestion of TUMS (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_777;
Consumption of supplements may be overlooked when investigating hypercalcemia andshould be specifically asked about. In addition, providers should be aware of EKG changes found in hypercalcemia to avoid unnecessary cardiac intervention.
- |||||||||| carvedilol / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
Solitary Fibrous Tumor in an Asymptomatic Patient Followed for 14 Years (Walter E. Washington Convention Center, Area J, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_8738; Malignancy markers are: age, tumor size, mitotic activity, presence of necrosis and nuclear pleomorphism. The gold standard treatment is surgical resection with free margins.
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Journal: Hydrochlorothiazide/Losartan Potassium Tablet Prepared by Direct Compression. (Pubmed Central) - Aug 27, 2022 1 tablet and the Hyzaar tablet in HCTZ, losartan carboxylic acid (E-3174), and LOS-K (F < F). Thus, formulation and preparation factors were determined according to the combination of the compression and mechanical properties of the mixed powder and quality of tablets, which was demonstrated to be a feasible method in direct powder compression.
- |||||||||| dapsone / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
Journal: A Rare Culprit of Methemoglobinemia. (Pubmed Central) - Aug 22, 2022 In this case, there was an acute rise in methemoglobin levels following initiation of an hydrochlorothiazide-losartan combination, which improved following the discontinuation of hydrochlorothiazide. Extensive workup ruled out cytochrome b5 reductase (Cb5R) and Glucose-6-phosphate dehydrogenase (G6PD) deficiency, which raised the suspicion of hydrochlorothiazide-induced methemoglobinemia, as it is part of the sulfa drug family.
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - Jul 27, 2022 P3, N=636, Suspended, Extensive workup ruled out cytochrome b5 reductase (Cb5R) and Glucose-6-phosphate dehydrogenase (G6PD) deficiency, which raised the suspicion of hydrochlorothiazide-induced methemoglobinemia, as it is part of the sulfa drug family. Trial completion date: Mar 2023 --> Oct 2023 | Recruiting --> Suspended | Trial primary completion date: Nov 2022 --> Jul 2023
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
DIAGNOSTIC DILEMMA : SPORADIC VS GENETIC CAUSES OF HYPOKALEMIC HYPERTENSION () - Mar 19, 2022 - Abstract #NKFSCM2022NKF_SCM_921; She was on losartan, hydrochlorothiazide, amlodipine...This test is useful to rule out extrarenal losses and diuretic abuse in hypokalemia, specifically with mildly increased aldosterone levels. CONCLUSION Careful evaluation is needed for persistent HTN
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: NICHE: N-of-1 Trials In Children With Hypertension (clinicaltrials.gov) - May 4, 2021 P4, N=49, Completed, The UV-Vis LED was shown to be a good light source in the photo-Fenton process. Recruiting --> Completed | N=80 --> 49 | Trial completion date: May 2024 --> May 2021 | Trial primary completion date: May 2024 --> Nov 2020
- |||||||||| amlodipine/atorvastatin / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
Clinical, Review, Journal: Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients. (Pubmed Central) - Apr 27, 2021 Uniquely, findings in a largely non-Hispanic Black patient population, offer an opportunity to examine this approach to combat important disparities in care in an underserved U.S. community. Further outcomes-based studies are warranted to explore the validity of these results and long-term safety of polypill treatment and are likely necessary prior to FDA approval and availability of a polypill product.
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Trial completion date, Trial primary completion date: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - Mar 22, 2021 P3, N=636, Recruiting, Further outcomes-based studies are warranted to explore the validity of these results and long-term safety of polypill treatment and are likely necessary prior to FDA approval and availability of a polypill product. Trial completion date: Mar 2021 --> Mar 2023 | Trial primary completion date: Dec 2020 --> Nov 2022
- |||||||||| labetalol / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
[VIRTUAL] An Unusual Case of Paradoxical Refractory Hyperreninemic Hypertension Induced by Antihypertensive Medication () - Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_474; METHODS A 31 year old female with history of infertility,hirsutism and obesity was evaluated for 2 year history of resistant hypertension.Despite a stepwise escalation to her current medication regimen of Losartan/Hydrochlorothiazide(Hyzaar) 100/25mg and Amlodipine 5mg, her blood pressure remained markedly elevated to 180s/120s...This was substituted for labetalol and doxazosin, which resulted in optimal BP control...This should be managed by sustained angiotensin blockade or sympatholytic agents. CONCLUSION It should be highlighted that sodium-depleting diuretics may lead to reactive hyperreninemia which paradoxically blunts it’s blood pressure lowering effect.
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Trial completion date, Trial primary completion date: NICHE: N-of-1 Trials In Children With Hypertension (clinicaltrials.gov) - Sep 3, 2020 P4, N=80, Recruiting, Even in cases where there was no total remission of the diseases, there was a significant drop in the use of medicines used for their treatment. Trial completion date: Jan 2020 --> May 2024 | Trial primary completion date: Jan 2020 --> May 2024
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Trial completion date, Trial primary completion date: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - May 24, 2019 P3, N=636, Not yet recruiting, Trial completion date: May 2019 --> Dec 2020 | Trial primary completion date: May 2019 --> Dec 2020 Trial completion date: Mar 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Oct 2020
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: The SCCS Polypill Pilot Trial (clinicaltrials.gov) - Aug 13, 2018 P2, N=303, Completed, Trial completion date: Mar 2019 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Oct 2020 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Enrollment open: NICHE: N-of-1 Trials In Children With Hypertension (clinicaltrials.gov) - May 1, 2018 P4, N=80, Recruiting, Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2018 | Trial primary completion date: Dec 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Trial initiation date, Trial primary completion date: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - Jan 5, 2018 P3, N=636, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: May 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| amlodipine/atorvastatin / Generic mfg., losartan/ hydrochlorothiazide / Generic mfg.
Enrollment closed: The SCCS Polypill Pilot Trial (clinicaltrials.gov) - Nov 6, 2017 P2, N=300, Active, not recruiting, Initiation date: May 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- |||||||||| losartan/ hydrochlorothiazide / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: Comparison of Losartan Associated With Indapamide Versus Hyzaar (clinicaltrials.gov) - Jan 30, 2017 P3, N=636, Not yet recruiting, Recruiting --> Completed | Trial primary completion date: Sep 2016 --> May 2016 N=255 --> 636 | Initiation date: Jan 2014 --> May 2017 | Trial primary completion date: Jun 2014 --> Dec 2017
|